|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC7A1 |
Gene summary for SLC7A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC7A1 | Gene ID | 6541 |
| Gene name | solute carrier family 7 member 1 | |
| Gene Alias | ATRC1 | |
| Cytomap | 13q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | A0A024RDQ9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6541 | SLC7A1 | CA_HPV_3 | Human | Cervix | CC | 7.43e-05 | 1.83e-01 | 0.0414 |
| 6541 | SLC7A1 | CCI_2 | Human | Cervix | CC | 2.13e-04 | 7.89e-01 | 0.5249 |
| 6541 | SLC7A1 | CCI_3 | Human | Cervix | CC | 1.41e-11 | 1.25e+00 | 0.516 |
| 6541 | SLC7A1 | AEH-subject1 | Human | Endometrium | AEH | 8.33e-25 | 6.44e-01 | -0.3059 |
| 6541 | SLC7A1 | AEH-subject2 | Human | Endometrium | AEH | 3.67e-02 | 2.71e-01 | -0.2525 |
| 6541 | SLC7A1 | AEH-subject5 | Human | Endometrium | AEH | 2.36e-38 | 9.14e-01 | -0.2953 |
| 6541 | SLC7A1 | EEC-subject1 | Human | Endometrium | EEC | 1.98e-22 | 6.54e-01 | -0.2682 |
| 6541 | SLC7A1 | EEC-subject2 | Human | Endometrium | EEC | 5.49e-03 | 2.83e-01 | -0.2607 |
| 6541 | SLC7A1 | EEC-subject4 | Human | Endometrium | EEC | 7.37e-19 | 6.37e-01 | -0.2571 |
| 6541 | SLC7A1 | EEC-subject5 | Human | Endometrium | EEC | 4.19e-10 | 4.44e-01 | -0.249 |
| 6541 | SLC7A1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 6.80e-06 | 1.34e-01 | -0.1869 |
| 6541 | SLC7A1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 5.99e-05 | -2.10e-02 | -0.1883 |
| 6541 | SLC7A1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.91e-02 | 8.72e-02 | -0.1934 |
| 6541 | SLC7A1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.90e-08 | 7.32e-02 | -0.1917 |
| 6541 | SLC7A1 | LZE4T | Human | Esophagus | ESCC | 3.74e-10 | -1.92e-01 | 0.0811 |
| 6541 | SLC7A1 | LZE8T | Human | Esophagus | ESCC | 3.32e-04 | -1.78e-01 | 0.067 |
| 6541 | SLC7A1 | LZE20T | Human | Esophagus | ESCC | 4.52e-04 | -2.89e-01 | 0.0662 |
| 6541 | SLC7A1 | LZE24T | Human | Esophagus | ESCC | 6.26e-08 | 1.97e-02 | 0.0596 |
| 6541 | SLC7A1 | P2T-E | Human | Esophagus | ESCC | 6.00e-13 | 1.54e-01 | 0.1177 |
| 6541 | SLC7A1 | P4T-E | Human | Esophagus | ESCC | 9.48e-18 | 2.10e-01 | 0.1323 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190040718 | Oral cavity | OSCC | regulation of cellular response to oxidative stress | 47/7305 | 89/18723 | 5.62e-03 | 2.17e-02 | 47 |
| GO:190320118 | Oral cavity | OSCC | regulation of oxidative stress-induced cell death | 40/7305 | 74/18723 | 6.09e-03 | 2.30e-02 | 40 |
| GO:00436484 | Oral cavity | OSCC | dicarboxylic acid metabolic process | 50/7305 | 96/18723 | 6.24e-03 | 2.35e-02 | 50 |
| GO:00706618 | Oral cavity | OSCC | leukocyte proliferation | 145/7305 | 318/18723 | 9.31e-03 | 3.33e-02 | 145 |
| GO:00075969 | Oral cavity | OSCC | blood coagulation | 102/7305 | 217/18723 | 9.69e-03 | 3.43e-02 | 102 |
| GO:003647510 | Oral cavity | OSCC | neuron death in response to oxidative stress | 19/7305 | 31/18723 | 9.93e-03 | 3.48e-02 | 19 |
| GO:0021591 | Oral cavity | OSCC | ventricular system development | 18/7305 | 29/18723 | 1.00e-02 | 3.49e-02 | 18 |
| GO:190320310 | Oral cavity | OSCC | regulation of oxidative stress-induced neuron death | 17/7305 | 27/18723 | 1.01e-02 | 3.49e-02 | 17 |
| GO:190288218 | Oral cavity | OSCC | regulation of response to oxidative stress | 50/7305 | 98/18723 | 1.03e-02 | 3.53e-02 | 50 |
| GO:00466517 | Oral cavity | OSCC | lymphocyte proliferation | 131/7305 | 288/18723 | 1.41e-02 | 4.67e-02 | 131 |
| GO:00075999 | Oral cavity | OSCC | hemostasis | 103/7305 | 222/18723 | 1.45e-02 | 4.73e-02 | 103 |
| GO:00508179 | Oral cavity | OSCC | coagulation | 103/7305 | 222/18723 | 1.45e-02 | 4.73e-02 | 103 |
| GO:00706657 | Oral cavity | OSCC | positive regulation of leukocyte proliferation | 72/7305 | 150/18723 | 1.53e-02 | 4.95e-02 | 72 |
| GO:00068572 | Oral cavity | OSCC | oligopeptide transport | 11/7305 | 16/18723 | 1.56e-02 | 4.99e-02 | 11 |
| GO:0045785110 | Oral cavity | LP | positive regulation of cell adhesion | 134/4623 | 437/18723 | 2.44e-03 | 1.74e-02 | 134 |
| GO:004211017 | Oral cavity | LP | T cell activation | 146/4623 | 487/18723 | 4.13e-03 | 2.66e-02 | 146 |
| GO:000697918 | Prostate | BPH | response to oxidative stress | 142/3107 | 446/18723 | 8.11e-16 | 1.36e-13 | 142 |
| GO:006219718 | Prostate | BPH | cellular response to chemical stress | 110/3107 | 337/18723 | 2.44e-13 | 2.40e-11 | 110 |
| GO:004206018 | Prostate | BPH | wound healing | 123/3107 | 422/18723 | 5.74e-11 | 3.59e-09 | 123 |
| GO:003459918 | Prostate | BPH | cellular response to oxidative stress | 90/3107 | 288/18723 | 4.70e-10 | 2.43e-08 | 90 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC7A1 | SNV | Missense_Mutation | c.623N>A | p.Gly208Glu | p.G208E | P30825 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC7A1 | insertion | Nonsense_Mutation | novel | c.1165_1166insTTTAAATTTGTTTTAGTTGCAGTGATCTAGAGGGGCTTGA | p.Thr389IlefsTer2 | p.T389Ifs*2 | P30825 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SLC7A1 | insertion | Frame_Shift_Ins | novel | c.1601_1602insTAAAT | p.Ser535LysfsTer37 | p.S535Kfs*37 | P30825 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| SLC7A1 | insertion | In_Frame_Ins | novel | c.1600_1601insTCCCTCCGGGGTGGTGGGATGCTTCTC | p.Gly534delinsValProProGlyTrpTrpAspAlaSerArg | p.G534delinsVPPGWWDASR | P30825 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| SLC7A1 | insertion | In_Frame_Ins | novel | c.373_374insAAACGATGAGAGGCGTCCATGGCAGAGCAGTGGTCT | p.Thr125delinsLysThrMetArgGlyValHisGlyArgAlaValValSer | p.T125delinsKTMRGVHGRAVVS | P30825 | protein_coding | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| SLC7A1 | SNV | Missense_Mutation | novel | c.874G>A | p.Ala292Thr | p.A292T | P30825 | protein_coding | tolerated(0.29) | possibly_damaging(0.555) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC7A1 | SNV | Missense_Mutation | c.308N>C | p.Val103Ala | p.V103A | P30825 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SLC7A1 | SNV | Missense_Mutation | rs767310993 | c.817N>A | p.Ala273Thr | p.A273T | P30825 | protein_coding | deleterious(0.01) | probably_damaging(0.981) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC7A1 | SNV | Missense_Mutation | rs548607156 | c.1633N>A | p.Val545Ile | p.V545I | P30825 | protein_coding | tolerated(1) | benign(0) | TCGA-WL-A834-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| SLC7A1 | SNV | Missense_Mutation | c.44G>A | p.Arg15Gln | p.R15Q | P30825 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-3810-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |